In SLE, Adding Dapirolizumab Pegol Vs. Placebo to Usual Care Improved Disease Activity at 48 Wk.
Francisco R Lafita,Ami Schattner, ACP Journal Club Editorial Team at McMaster University Annals of internal medicine（2026）SCI 1区
Hospital Viamed Tarragona and Centre Mèdic Millenium Imperial
摘要
CLINICAL IMPACT RATINGS:GIM/FP/GP: [Formula: see text] Rheumatology: [Formula: see text].
更多查看译文
原文链接
分享
引用
